Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

被引：17

作者：

Sahebi, Firoozeh ^{[1
]}

Iacobelli, Simona ^{[2
]}

Sbianchi, Giulia ^{[2
]}

Koster, Linda ^{[3
]}

Blaise, Didier ^{[4
]}

Remenyi, Peter ^{[5
]}

Russell, Nigel H. ^{[6
]}

Ljungman, Per ^{[7
]}

Kobbe, Guido ^{[8
]}

Apperley, Jane ^{[9
]}

Trneny, Marek ^{[10
]}

Krejci, Marta ^{[11
]}

Wiktor-Jedrzejczak, Wieslaw ^{[12
]}

Sanchez, James F. ^{[1
]}

Schaap, Nicolaas ^{[13
]}

Isaksson, Cecilia ^{[14
]}

Lenhoff, Stig ^{[15
]}

Browne, Paul ^{[16
]}

Scheid, Christof ^{[17
]}

Wilson, Keith M. O. ^{[18
]}

Yakoub-Agha, Ibrahim ^{[19
]}

Muniz, Soledad Gonzalez ^{[20
]}

Schoenland, Stefan ^{[21
]}

Morris, Curly ^{[22
]}

Garderet, Laurent ^{[23
]}

Kroeger, Nicolaus ^{[24
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 Duarte Rd, Duarte, CA 91010 USA

[2] Univ Roma Tor Vergata, Dept Biol, Rome, Italy

[3] EBMT Data Off Leiden, Leiden, Netherlands

[4] Ctr Rech Cancerol Marseille, Inst Paoli Calmettes, Dept Hematol, Marseille, France

[5] St Istvan & St Laszlo Hosp, Budapest, Hungary

[6] Nottingham Univ Hosp, Dept Haematol, Nottingham, England

[7] Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden

[8] Heinrich Heine Univ, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[9] Imperial Coll, Hammersmith Hosp, Dept Haematol, London, England

[10] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[11] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[12] Cent Clin Hosp, Dept Hematol Oncol & Internal Med, Warsaw, Poland

[13] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands

[14] Umea Univ Hosp, Dept Hematol, Umea, Sweden

[15] Skane Univ Hosp, Dept Hematol, Lund, Sweden

[16] St James Hosp, Dept Haematol, Dublin, Ireland

[17] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[18] Univ Hosp Wales, Dept Haematol, Cardiff, S Glam, Wales

[19] CHRU Lille, Dept Hematol, Lille, France

[20] Hosp Univ Cent Asturias, Dept Hematol, Oviedo, Spain

[21] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany

[22] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[23] Hosp St Antoine, Dept Hematol & Cellular Therapy, Paris, France

[24] Univ Hosp Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 05期

关键词：

Multiple myeloma; Second primary malignancies; Immunomodulatory drugs; Proteasome inhibitors; Plerixafor; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; MYELODYSPLASTIC SYNDROME; THERAPY; SECONDARY; NEOPLASMS; LEUKEMIA; RISK;

D O I：

10.1016/j.bbmt.2018.01.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM5). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPM5, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM. (C) 2018 American Society for Blood and Marrow Transplantation.

引用

页码：930 / 936

页数：7

共 25 条

[1] The risk of secondary primary malignancies after therapy for multiple myeloma [J].

Areethamsirikul, Nuchanan ;

Reece, Donna E. .

LEUKEMIA & LYMPHOMA, 2015, 56 (11) :3012-3021

[2] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[3] CHEMOTHERAPY OF PLASMA-CELL MYELOMA AND THE INCIDENCE OF ACUTE-LEUKEMIA [J].

BERGSAGEL, DE ;

BAILEY, AJ ;

LANGLEY, GR ;

MACDONALD, RN ;

WHITE, DF ;

MILLER, AB .

NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (14) :743-748

[4]

Chakraborty S, 2012, ANTICANCER RES, V32, P4507

[5] A COMPARISON OF THE INCIDENCE OF THE MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID-LEUKEMIA FOLLOWING MELPHALAN AND CYCLOPHOSPHAMIDE TREATMENT FOR MYELOMATOSIS - A REPORT TO THE MEDICAL-RESEARCH-COUNCILS WORKING PARTY ON LEUKEMIA IN ADULTS [J].

CUZICK, J ;

ERSKINE, S ;

EDELMAN, D ;

GALTON, DAG .

BRITISH JOURNAL OF CANCER, 1987, 55 (05) :523-529

[6] Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms [J].

C Dong ;

K Hemminki .

British Journal of Cancer, 2001, 85 (7) :997-1005

[7] Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years [J].

Engelhardt, Monika ;

Ihorst, Gabriele ;

Landgren, Ola ;

Pantic, Milena ;

Reinhardt, Heike ;

Waldschmidt, Johannes ;

May, Annette M. ;

Schumacher, Martin ;

Kleber, Martina ;

Waesch, Ralph .

HAEMATOLOGICA, 2015, 100 (10) :1340-1349

[8]

Howlader N., 1975, SEER CANC STAT REV 1

[9] Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial [J].

Jones, J. R. ;

Cairns, D. A. ;

Gregory, W. M. ;

Collett, C. ;

Pawlyn, C. ;

Sigsworth, R. ;

Striha, A. ;

Henderson, R. ;

Kaiser, M. F. ;

Jenner, M. ;

Cook, G. ;

Russell, N. H. ;

Williams, C. ;

Pratt, G. ;

Kishore, B. ;

Lindsay, J. ;

Drayson, M. T. ;

Davies, F. E. ;

Boyd, K. D. ;

Owen, R. G. ;

Jackson, G. H. ;

Morgan, G. J. .

BLOOD CANCER JOURNAL, 2016, 6 :e506-e506

[10] Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients [J].

Kumar, S. K. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Pandey, S. ;

Kapoor, P. ;

Dingli, D. ;

Hayman, S. R. ;

Leung, N. ;

Lust, J. ;

McCurdy, A. ;

Russell, S. J. ;

Zeldenrust, S. R. ;

Kyle, R. A. ;

Rajkumar, S. V. .

LEUKEMIA, 2014, 28 (05) :1122-1128

← 1 2 3 →